Dr. Mark Kieran, MD

• Pediatric Hematology & Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Childrens Hospital

  Fellowship Hospital

• Boston Children's Hospital/dana-farber Cancer Institute

  Fellowship Hospital, 1995

• Mcgill University

  Residency Hospital, 1992

• University Of Calgary School Of Medicine

  Medical School, 1986

• University Of Calgary Faculty Of Medicine

  Medical School, 1986

• Recurrent somatic alterations ofFGFR1andNTRK2in pilocytic astrocytoma, 2013-06-30

• A Phase I and Biology Study of Gefitinib and Radiation in Children with Newly Diagnosed Brain Stem Gliomas or Supratentorial Malignant Gliomas, 2010-08-12

• MYB-QKI rearrangements in Angiocentric Glioma drive tumorigenicity through a tripartite mechanism, 2016-02-01

• Clinical Trial of Protein Farnesylation Inhibitors Lonafarnib, Pravastatin and Zoledronic Acid in Children with Hutchinson-Gilford Progeria Syndrome, 2016-07-12

• DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues, 2012-06-15

• Proceedings from the 2009 Genetic Syndromes of the Ras/MAPK Pathway: From Bedside to Bench and Back, 2012-07-17

• Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas, 2014-09-09

• Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival, 2017-07-21

• Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic, 2015-07-01

• PPARa Deficiency in Inflammatory Cells Suppresses Tumor Growth, 2007-02-28

• Bone Density in Post-Pubertal Adolescent Survivors of Childhood Brain Tumors, 2011-08-29

• Hutchinson-Gilford Progeria Is a Skeletal Dysplasia, 2017-07-14

• Phase I Study of SU5416, a Small Molecule Inhibitor of the Vascular Endothelial Growth Factor Receptor (VEGFR) in Refractory Pediatric Central Nervous System Tumors, 2009-10-30

• Specific uptake of99mTc-NC100692, an avß3-targeted imaging probe, in subcutaneous and orthotopic tumors, 2013-05-20

• Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition, 2014-03-17

• Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma, 2010-10-15

• The Integration of Biology Into the Treatment of Diffuse Intrinsic Pontine Glioma: A Review of the North American Clinical Trial Perspective, 2018-05-18

• Challenges to curing primary brain tumours, 2019-02-07

• Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma, 2019-06-03

• The decision-making process and criteria in selecting candidate drugs for progeria clinical trials, 2016-05-27

• Structural variants shape driver combinations and outcomes in pediatric high-grade glioma, 2022-07-04

• Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells, 2019-08-19

• BET-bromodomain inhibition ofMYC-amplified medulloblastoma, 2013-12-02

• Challenges to curing primary brain tumours, 2019-07-10

• Chemotherapy-generated cell debris stimulates colon carcinoma tumor growthviaosteopontin, 2018-06-29

• Clinical, pathological and molecular characterization of infant medulloblastomas treated with sequential high-dose chemotherapy, 2016-05-04

• Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas, 2014-01-12

• Phase II Trial of Pirfenidone in Children and Young Adults With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas, 2014-04-22

• Recurrent somatic mutations inACVR1in pediatric midline high-grade astrocytoma, 2014-04-06

• Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples, 2009-11-18

• PROTEOMIC PROFILING OF CEREBROSPINAL FLUID IDENTIFIES PROSTAGLANDIN D2 SYNTHASE AS A PUTATIVE BIOMARKER FOR PEDIATRIC MEDULLOBLASTOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY, 2011-01-27

• A Phase 1 Pharmacokinetic Optimal Dosing Study of Intraventricular Topotecan for Children with Neoplastic Meningitis: A Pediatric Brain Tumor Consortium Study, 2012-09-21

• Pediatric low-grade gliomas: How modern biology reshapes the clinical field, 2014-02-28

• PPARs: A Double-Edged Sword in Cancer Therapy?, 2009-06-29

• Parent-perceived child cognitive function: results from a sample drawn from the US general population, 2010-07-23

• Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imaging, 2014-07-25

• A Prospective Study of Radiographic Manifestations in Hutchinson-Gilford Progeria Syndrome, 2012-07-01

• Absence of Oncogenic Canonical Pathway Mutations in Aggressive Pediatric Rhabdoid Tumors, 2012-09-19

• A novelGIT2-BRAFfusion in pilocytic astrocytoma, 2017-11-15

• Initial Cutaneous Manifestations of Hutchinson-Gilford Progeria Syndrome, 2014-01-24

• Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma, 2011-10-25

• Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas, 2011-01-19

• Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq, 2018-04-20

• A POETIC Phase II study of continuous oral everolimus in recurrent, radiographicallyprogressive pediatric low-grade glioma, 2020-11-02

• A Phase I trial and PK Study of Cediranib (AZD2171), an Orally Bioavailable Pan-VEGFR Inhibitor, in Children with Recurrent or Refractory Primary CNS Tumors, 2015-07-19